TAIPEI, Taiwan, Dec. 22, 2017 /PRNewswire/ -- OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that uniquely target Globo Series (including Globo H) and AKR1C3, announced that it will participate at the...
from PR Newswire: //www.prnewswire.co.uk/news-releases/obi-pharma-announces-participation-at-the-36th-jp-morgan-annual-healthcare-conference-in-san-francisco-665869753.html
No comments:
Post a Comment